{
  "id": "5a8718c861bb38fb24000008",
  "type": "factoid",
  "question": "What are check point inhibitors?",
  "ideal_answer": "Immune checkpoint blocking monoclonal antibodies are heralded as a promising therapeutic approach in clinical oncology. These mAbs do not directly attack the malignant cells as most anticancer mAbs; rather, they enhance the anti-tumor response of the immune system by targeting immune regulatory pathways.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24485523",
    "http://www.ncbi.nlm.nih.gov/pubmed/27403706",
    "http://www.ncbi.nlm.nih.gov/pubmed/28363334",
    "http://www.ncbi.nlm.nih.gov/pubmed/26942589",
    "http://www.ncbi.nlm.nih.gov/pubmed/27528363",
    "http://www.ncbi.nlm.nih.gov/pubmed/28878676",
    "http://www.ncbi.nlm.nih.gov/pubmed/26321371",
    "http://www.ncbi.nlm.nih.gov/pubmed/28351171",
    "http://www.ncbi.nlm.nih.gov/pubmed/27654928",
    "http://www.ncbi.nlm.nih.gov/pubmed/28865357"
  ],
  "snippets": [
    {
      "text": " Immune checkpoint blocking monoclonal antibodies are heralded as a promising therapeutic approach in clinical oncology. These mAbs do not directly attack the malignant cells as most anticancer mAbs; rather, they enhance the anti-tumor response of the immune system by targeting immune regulatory pathways.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28363334",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " These next generation agents with novel mechanisms of action as well as targeted therapies are being used both in the preclinical and clinical settings for patients with myeloma. These agents include monoclonal antibodies, deacetylase inhibitors, kinase inhibitors, agents affecting various signaling pathways, immune check point inhibitors, and other targeted therapies",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27654928",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Immune check-point inhibitors should be considered a promising treatment option in GBM.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Immune check-point inhibitors are now employed as single-agents in current practice for the treatment of advanced non-small cell lung cancer (NSCLC), while combinations of different inhibitors are being evaluated in clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28351171",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Check point antibody inhibitors, such as anti-PD-1/PD-L1, are a novel class of inhibitors that function as a tumor suppressing factor via modulation of immune cell-tumor cell interaction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The recent successes of immune check point targeting therapies in treating cancer patients has driven a resurgence of interest in targeting these pathways in chronically infected patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865357",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These checkpoint blockers are rapidly becoming a highly promising cancer therapeutic approach that yields remarkable antitumor responses with limited side effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The survival of tumors in several cases is assisted by checkpoint immunomodulation to maintain the imbalance between immune surveillance and cancer cell proliferation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Check point inhibitors have promising activity in several solid tumors and have demonstrated a favorable toxicity profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26942589",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The treatment of melanoma is evolving rapidly over the past few years. Patients with BRAFv600 mutations can be treated with a combination of a BRAF-inhibitor and an MEK-inhibitor. Patients with BRAF wild-type tumors and BRAFv600 mutated tumors can be treated with immunotherapy i.e. check point inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27403706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Till now, the prognosis of advanced gastric cancer looked dreadful; thus the search for newer better approaches for this lethal disease has been a strategic target for cancer researchers. In recent years, important immunobiological aspects of the tumor have been revealed with the subsequent proposal of immune check point inhibitors to target these pathways.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321371",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inhibitory receptors on immune system cells respond to membrane-bound and soluble ligands to abort or mitigate the intensity of immune responses by raising thresholds of activation, halting proliferation, favoring apoptosis or inhibiting/deviating effector function differentiation. Such evolutionarily selected inhibitory mechanisms are termed check-points and therefore check-point inhibitors empower any ongoing anti-cancer immune response that might have been too weak or exhausted.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24485523",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "monoclonal antibody drugs that regulate the immune response to cancer"
}